We are live on ! Find out more
PTCT icon

PTC Therapeutics

157 hedge funds and large institutions have $1.91B invested in PTC Therapeutics in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 51 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

30% more capital invested

Capital invested by funds: $1.47B → $1.91B (+$446M)

19% more funds holding

Funds holding: 132157 (+25)

0% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 51

20% less call options, than puts

Call options by funds: $29M | Put options by funds: $36.4M

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
157
Holders Change
+25
Holders Change %
+18.94%
% of All Funds
4.18%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
46
Increased
51
Reduced
51
Closed
21
Calls
$29M
Puts
$36.4M
Net Calls
-$7.46M
Net Calls Change
-$5.77M
Name Holding Trade Value Shares
Change
Change in
Stake
O
26
OppenheimerFunds
New York
$18.1M -$1.17M -19,150 -6%
AIMCA
27
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$17.3M +$17.4M +284,722 New
TAL
28
TIG Advisors LLC
New York
$16.8M +$16.9M +276,721 New
AllianceBernstein
29
AllianceBernstein
Tennessee
$13M +$11M +179,610 +538%
Artisan Partners
30
Artisan Partners
Wisconsin
$11.1M +$11.2M +183,024 New
Two Sigma Investments
31
Two Sigma Investments
New York
$10.8M +$10.8M +177,749 New
CNB
32
City National Bank
California
$9.97M -$731K -11,975 -7%
Deutsche Bank
33
Deutsche Bank
Germany
$8.89M +$4.49M +73,512 +101%
Geode Capital Management
34
Geode Capital Management
Massachusetts
$8.83M -$60.1K -985 -0.7%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$8.45M -$570K -9,349 -6%
Norges Bank
36
Norges Bank
Norway
$8.15M +$8.17M +133,884 New
HCM
37
Highbridge Capital Management
New York
$7.93M +$6.34M +103,862 +392%
PAMU
38
Pictet Asset Management (UK)
United Kingdom
$7.44M -$4.48M -73,508 -37%
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$7.38M +$7.4M +121,315 New
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$6.78M +$5.83M +95,589 +606%
CCM
41
Cupps Capital Management
Illinois
$6.68M -$1.54M -25,304 -19%
GIM
42
Granahan Investment Management
Massachusetts
$6.39M -$46.6M -764,101 -88%
Asset Management One
43
Asset Management One
Japan
$6.34M -$312K -5,116 -5%
TCIM
44
TIAA CREF Investment Management
New York
$5.92M +$92.9K +1,522 +2%
CS
45
Candriam SCA
Luxembourg
$5.9M -$183K -3,000 -3%
BIM
46
BlackRock Investment Management
Delaware
$5.84M +$341K +5,590 +6%
JP Morgan Chase
47
JP Morgan Chase
New York
$5.68M +$1.08M +17,638 +23%
Invesco
48
Invesco
Georgia
$5.67M -$428K -7,007 -7%
GC
49
Guggenheim Capital
Illinois
$5.55M +$63.5K +1,040 +1%
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$5.06M -$6.33M -103,677 -55%

PTCT Hedge Fund Activity: Q1 2015 in Review

157 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2015, worth a combined $1.91B — up 30% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new PTCT positions and 21 closed out — a net gain of 25 holders — while 51 added to existing stakes and 51 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $98.4M. The largest seller was Granahan Investment Management, cutting an estimated $46.6M.

  • 157 institutional investors held PTC Therapeutics (PTCT) as of Q1 2015, up from 132 in Q4 2014.
  • Funds reported $1.91B of PTC Therapeutics stock for Q1 2015, up 30% quarter-over-quarter.
  • 46 funds opened new PTC Therapeutics positions in Q1 2015 and 21 closed out, a net change of +25 holders.
  • The largest PTC Therapeutics buyer in Q1 2015 was Westfield Capital Management, an estimated $98.4M added.
  • The largest PTC Therapeutics seller in Q1 2015 was Granahan Investment Management, an estimated $46.6M sold.

Based on aggregated 13F filings for Q1 2015.